Suppr超能文献

5-苄基阿糖胞苷在生化效应和代谢方面的物种依赖性差异。

Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.

作者信息

Davis S T, Joyner S S, Chandrasurin P, Baccanari D P

机构信息

Division of Molecular Genetics and Microbiology, Burroughs Wellcome Co., Research Triangle Park, NC 27709.

出版信息

Biochem Pharmacol. 1993 Jan 7;45(1):173-81. doi: 10.1016/0006-2952(93)90390-i.

Abstract

The pharmacokinetics and biochemical effects of the uridine phosphorylase (UrdPase) inhibitor 5-benzylacyclouridine (BAU) were investigated in the mouse, rat and monkey. Following i.p. administration of BAU (30 mg/kg) in the mouse and i.v. administration in the rat and monkey, initial BAU plasma half-life values were 36, 36 and 25 min, and the areas under the plasma BAU concentration versus time curves (AUC) were 127, 80 and 76 microM.hr, respectively. Rats were also dosed p.o. and i.v. with BAU at 90 mg/kg, and a comparison of the AUC values showed an oral bioavailability of 70%. Analyses of plasma samples by HPLC indicated that the metabolism of BAU differed in these species. A major BAU metabolite was observed in monkeys. Its concentration was greater than or equal to that of BAU in almost every plasma sample, and its elimination paralleled that of BAU. Urinary recovery of the metabolite was 10-fold higher than the recovery of unchanged drug. The compound was identified as the ether glucuronide of BAU by its UV absorption spectrum, its co-elution with BAU after incubation with beta-glucuronidase, and liquid chromatography/mass spectrum analysis. A different metabolite was detected in rat plasma; its maximum concentration was 15% of the BAU level, and its elution position on the HPLC chromatogram was not affected by the action of beta-glucuronidase. BAU had equivalent potency against UrdPase in liver extracts from the three species, with Ki values of about 0.17 microM. However, the in vivo effects of BAU on plasma uridine concentrations were species dependent. In mice, a 30 mg/kg i.p. dose of BAU increased the plasma uridine concentration to 11 microM from a control level of 1.8 microM. In the rat, a 30 mg/kg i.v. dose of BAU increased plasma uridine to 2.1 from 1.1 microM control levels, and a 300 mg/kg oral dose resulted in a peak plasma uridine concentration of only 6 microM. In the monkey, BAU (30 mg/kg, i.v.) had no effect on plasma uridine despite the presence of 10-100 microM BAU levels in plasma for 1.5 hr. These data show that there are significant differences in the biochemical effects and metabolism of BAU in CD-1 mice, CD rats and cynomolgus monkeys.

摘要

在小鼠、大鼠和猴子体内研究了尿苷磷酸化酶(UrdPase)抑制剂5-苄基阿糖胞苷(BAU)的药代动力学和生化效应。小鼠腹腔注射BAU(30mg/kg),大鼠和猴子静脉注射后,BAU的初始血浆半衰期值分别为36、36和25分钟,血浆BAU浓度-时间曲线下面积(AUC)分别为127、80和76μM·hr。大鼠还经口和静脉给予90mg/kg的BAU,AUC值比较显示口服生物利用度为70%。通过高效液相色谱法(HPLC)分析血浆样本表明,BAU在这些物种中的代谢有所不同。在猴子体内观察到一种主要的BAU代谢产物。在几乎每个血浆样本中,其浓度均大于或等于BAU的浓度,并且其消除过程与BAU平行。该代谢产物的尿回收率比未改变药物的回收率高10倍。通过其紫外吸收光谱、与β-葡萄糖醛酸酶孵育后与BAU的共洗脱以及液相色谱/质谱分析,将该化合物鉴定为BAU的醚葡萄糖醛酸苷。在大鼠血浆中检测到一种不同的代谢产物;其最大浓度为BAU水平的15%,并且其在HPLC色谱图上的洗脱位置不受β-葡萄糖醛酸酶作用的影响。BAU对这三种物种肝脏提取物中的UrdPase具有同等效力,Ki值约为0.17μM。然而,BAU对血浆尿苷浓度的体内效应具有物种依赖性。在小鼠中,腹腔注射30mg/kg的BAU可使血浆尿苷浓度从对照水平的1.8μM增加至11μM。在大鼠中,静脉注射30mg/kg的BAU可使血浆尿苷从对照水平的1.1μM增加至2.1μM,口服300mg/kg的剂量导致血浆尿苷峰值浓度仅为6μM。在猴子中,尽管血浆中BAU水平在1.5小时内为10 - 100μM,但静脉注射BAU(30mg/kg)对血浆尿苷没有影响。这些数据表明,BAU在CD-1小鼠、CD大鼠和食蟹猴中的生化效应和代谢存在显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验